PAN India Service 

WHO Certified

Billion $ info… Worldwide drug in clinical trials YES Indication. YES Phase wise. YES Conducted by YES Contact no & mail id with the address of trial done by YES Sponsor. YES Molecule launching year ???? Contact us. courtesy centrewatch

Read more

While biosimilars’ growth potential appears bright, winning with biosimilars in emerging markets is not a simple undertaking.

While biosimilars’ growth potential appears bright, winning with biosimilars in emerging markets is not a simple undertaking. Companies seeking entry or expansion should craft a strategy to address the specific challenges in the emerging markets by choosing the right partner.

Read more While biosimilars’ growth potential appears bright, winning with biosimilars in emerging markets is not a simple undertaking.

MONITORING THE COLD / SUPPLY CHAIN, VHSPL : INTRODUCES THE TOTAL SOLUTION... • Today, ensuring Cold Chain Products are continuously stored, handled and transported under adequate environmental conditions (temperature) is crucial. • Automated Monitoring Systems now enable to monitor and track storage and transport conditions throughout the Supply Chain up to the end-users.

Read more

Latest news sub : Biologics Latest news sub : Biologics FDA chief says pharmas use rebates to block biosimilar competition Gottlieb: If Americans could have bought FDA-approved biosimilars last year, they could have saved more than $4.5 billion.  

Read more

Big Pharma vs Big Pharma in court battles over biosimilar drugs

Big Pharma vs Big Pharma in court battles over biosimilar drugs Big Pharma vs Big Pharma in court battles over biosimilar drugs Reuters - The line dividing makers of brand-name drugs and copycat medicines is blurring as companies known for innovative treatments queue up to peddle copies of rivals' complex biological medicines.

Read more Big Pharma vs Big Pharma in court battles over biosimilar drugs

Blood-based Tumour Mutational Burden Assay Predicts Clinical Benefit in NSCLC Patients Treated with Atezolizumab

Blood-based Tumour Mutational Burden Assay Predicts Clinical Benefit in NSCLC Patients Treated with Atezolizumab Results based on retrospective analysis of two large randomised trials I. Blood-based Tumour Mutational Burden Assay Predicts Clinical Benefit in NSCLC Patients Treated with Atezolizumab Results based on retrospective analysis of two large randomised trials. Date: 17 Aug 2018 II. Eisai, …

Read more Blood-based Tumour Mutational Burden Assay Predicts Clinical Benefit in NSCLC Patients Treated with Atezolizumab

Best Practices to Root Out Supply Chain unauthorised Infiltration & Export of Biologic & Bio-Similar.

Best Practices to Root Out Supply Chain unauthorised Infiltration & Export of Biologic & Bio-Similar. I. Set up a Whistle blower hotline. II. Observe staff activity. III. Undertake Management Reviews. of activities outside audit periods. IV Monitor annual leave. There are lots of evidence that a real ethical vendors are closed or worst affected by …

Read more Best Practices to Root Out Supply Chain unauthorised Infiltration & Export of Biologic & Bio-Similar.